First 10 runs free
    Intelligence Feed event · Equity · 2026-11-08

    Novo Nordisk and Lilly keep GLP-1 growth in focus

    Question

    Novo Nordisk and Lilly keep GLP-1 growth in focus

    Direct answer

    GLP-1 sales growth supports NVO and LLY multiple expansion, but the 47x P/E on LLY and the post-earnings move in NVO leave both names sensitive to valuation resets.

    Original publisher
    Market Ontology
    Evidence through
    2026-11-08
    Published
    2026-11-08
    Revision
    1 · 2026-11-08

    Cite as: Market Ontology, “Novo Nordisk and Lilly keep GLP-1 growth in focus”, revision 1, evidence through 2026-11-08. https://marketontology.com/market-events/2026-11-08/novo-nordisk-and-lilly-keep-glp-1-growth-in-focus-a93a8f

    EQUITY
    Novo Nordisk and Lilly keep GLP-1 growth in focus
    GLP-1 sales growth supports NVO and LLY multiple expansion, but the 47x P/E on LLY and the post-earnings move in NVO leave both names sensitive to valuation resets.
    NVOLLYIBB
    Impact
    72
    YESTERDAY
    SIG
    87%
    NVOLLYIBB
    Novo Nordisk and Lilly keep GLP-1 growth in focus
    GLP-1 sales growth supports NVO and LLY multiple expansion, but the 47x P/E on LLY and the post-earnings move in NVO leave both names sensitive to valuation resets.
    → GLP-1 sales growth supports NVO and LLY multiple expansion, but the 47x P/E on LLY and the post-earnings move in NVO leave both names sensitive to valuation resets.
    Impact
    GLP-1 sales growth supports NVO and LLY multiple expansion, but the 47x P/E on LLY and the post-earnings move in NVO leave both names sensitive to valuation resets.
    Affected
    NVOLLYIBB
    Transmission
    GLP-1 sales growth supports NVO and LLY multiple expansion, but the 47x P/E on LLY and the post-earnings move in NVO leave both names sensitive to valuation resets.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    NVOGLP-1 revenue growth and guidance liftUp1-4wNovo Nordisk reported Q3 2026 results, its oral weight-loss pill generated $810 million in revenue, prescriptions exceeded 3 million, and the company raised full-year guidance.
    LLYhigher full-year revenue guidance from GLP-1 salesUp1-4wEli Lilly raised its 2026 revenue guidance to $91-92 billion from $85-87 billion driven by Mounjaro and Zepbound.
    IBBpharma-biotech leadership within healthcareMixed1-4wThe feed contains healthcare ETF comparisons and large-cap pharma catalysts.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    Find trades for this development

    Screen tradable expressions of this catalyst against your horizon and constraints. Nothing is submitted without your review.

    First 10 runs free

    First 10 runs free

    See today's live cards

    Public pages are published 24 hours after the product shows them. The product shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open live cards